Allogene Therapeutics, Inc. — Investor Relations & Filings
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2026-05-28 | English | |
| 8-K | 2026-05-28 | English | |
| DEFA14A | 2026-05-20 | English | |
| 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-05-13 | English | |
| 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-15 | English | |
| 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47868448 | DEFA14A | 2026-05-28 | English | ||
| 47868481 | 8-K | 2026-05-28 | English | ||
| 46726629 | DEFA14A | 2026-05-20 | English | ||
| 45762022 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-05-13 | English | ||
| 34609865 | 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-15 | English | ||
| 34439500 | 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 34434910 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 34409554 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 32897513 | 4 - ALLOGENE THERAPEUTICS, INC. (0001737287) (Filer) | 2026-03-04 | English | ||
| 31528502 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31528553 | 4 Filing | 2026-02-04 | English | ||
| 31528550 | 4 Filing | 2026-02-04 | English | ||
| 31528532 | 4 Filing | 2026-02-04 | English | ||
| 31528520 | 4 Filing | 2026-02-04 | English | ||
| 31528515 | 4 Filing | 2026-02-04 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Centessa Pharmaceuticals plc
Clinical-stage pharmaceutical company developing medicines …
|
CNTA | GB | Manufacturing |
|
Century Therapeutics, Inc.
Develops iPSC-derived allogeneic cell therapies for cancer …
|
IPSC | US | Manufacturing |
|
Cereno Scientific AB
Clinical-stage biotech developing drugs for rare cardiovasc…
|
CRNO | SE | Manufacturing |
|
CERO THERAPEUTICS HOLDINGS, INC.
Immunotherapy company developing engineered T cell therapeu…
|
CERO | US | Manufacturing |
|
CERUS CORP
Develops pathogen inactivation technology to reduce transfu…
|
CERS | US | Manufacturing |
|
Cessatech A/S
A biotech company developing medicines for children's acute…
|
CESSA | DK | Manufacturing |
|
CF PharmTech
Develops and manufactures inhalation drugs and delivery sys…
|
2652 | CN | Manufacturing |
|
CF PharmTech, Inc.
Specialty pharmaceutical company developing complex inhalat…
|
2652 | HK | Manufacturing |
|
CG Invites Co., Ltd.
A biopharmaceutical company specializing in digital genomic…
|
083790 | KR | Manufacturing |
|
CG Oncology, Inc.
Develops bladder-sparing oncolytic immunotherapies for urol…
|
CGON | US | Manufacturing |
Allogene Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33378/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33378 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33378 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33378 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33378}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Allogene Therapeutics, Inc. (id: 33378)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.